Semax
MEHFPGP ACTH(4-10) analogue — CID 9811102; ≠ Adamax ≠ Selank; Russian stroke lit ≠ US FDA approval.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. Semax is the synthetic ACTH(4-10) analogue Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). PubChem CID 9811102 (hard-separate from Selank CID 11765600 and from unresolved Adamax); formula C37H51N9O10S / MW 813.9; CAS 80714-61-0. Semax ≠ Adamax (Adamax is a separate batch-D object / unresolved N-methyl/adamantane-related Semax derivative narrative — do not merge). Semax ≠ Selank. Russian stroke / cognitive program literature exists; do not assume a US FDA-approved stroke drug. This drawer marks papers. It is not use advice.
Bottom line
Human evidence includes Russian clinical reports on Semax at different stages of ischemic stroke. Mechanistic literature is largely rodent ischemia transcriptome / immune-vascular gene regulation, plus copper-coordination and Aβ-aggregation biophysical papers. Seized “cognitive peptide” analytical surveys may list Semax-class products without proving efficacy. Keep Selank joint-imaging papers from collapsing the two objects.
Papers
Human stroke / clinical-program
PMID 29798983 — Gusev 2018
Tested: efficacy of Semax in treatment of patients at different stages of ischemic stroke (clinical-program report).
Does not show: a US FDA-approved stroke indication, or identity with Adamax.
Ischemia / transcriptome (rodent)
PMID 24661604 — Medvedeva 2014
Tested: genome-wide transcriptional analysis of Semax effects on immune and vascular system genes in rat brain focal ischemia.
Does not show: human stroke approval.
PMID 28255762 — Medvedeva 2017
Tested: Semax regulation of immune-response gene expression during ischemic brain injury in rats.
Does not show: human RCT replacement for Gusev clinical-program data.
PMID 32580520 — Filippenkov 2020
Tested: transcriptome-level protective properties of ACTH(4-7)PGP (Semax) after cerebral ischemia-reperfusion in rats.
Does not show: human clinical endpoints.
PMID 34201112 — Sudarkina 2021
Tested: brain protein expression profile supporting protective effect of Semax in rat cerebral ischemia-reperfusion.
Does not show: human efficacy by proteomics alone.
Coordination chemistry / Aβ biophysics (secondary)
PMID 27586814 — Magrì 2016
Tested: influence of N-terminus acetylation of Semax on copper(II)/zinc(II) coordination and biological properties.
Does not show: a clinical Alzheimer’s indication.
PMID 35080861 — Sciacca 2022
Tested: Semax effects on copper-induced Aβ aggregation and amyloid formation in artificial membrane models.
Does not show: human AD trial efficacy.
Joint / analytical context
PMID 32342318 — Panikratova 2020
Tested: functional connectomic study of Selank and Semax effects.
Does not show: interchangeability of Selank and Semax.
PMID 31667971 — Vanhee 2020
Tested: occurrence of putative cognitive-enhancing research peptides in seized pharmaceutical preparations (analytical/control framing).
Does not show: efficacy of Semax.
PMID 33418449 — Glazova 2021
Tested: Semax attenuates behavioural/neurochemical alterations after early-life fluvoxamine exposure in rats.
Does not show: human pediatric or psychiatric approval.
What is not established
US FDA approval for stroke or cognition. Equivalence to Adamax or Selank. That rodent transcriptome signals equal worldwide labeled efficacy. Product identity of unlabeled “Semax” vials. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
29798983 24661604 28255762 32580520 34201112 27586814 35080861 32342318 31667971 33418449
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.